NovoCure NVCR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.05M-27.0% | -$136.23M+23.3% | -$177.65M-3.9% | -$170.95M-4.1% | -$164.19M+2.6% | ||
| $15.45M+5.5% | $14.65M+8.2% | $13.54M+9.8% | $12.33M+5.0% | $11.75M+4.5% | ||
| $138.29M+31.9% | $104.83M-29.1% | $147.77M-1.4% | $149.82M-3.7% | $155.5M-2.8% | ||
| -$26.88M+45.2% | -$49.03M-42.2% | -$34.48M+22.8% | -$44.68M-46.7% | -$30.46M-15.5% | ||
| $21.19M-20.5% | $26.65M-13.2% | $30.69M-14.1% | $35.72M-14.3% | $41.68M-2.7% | ||
| $451.5M+3.3% | $437.28M+455% | $78.74M+350% | $17.5M+104% | -$392.93M-180% | ||
| $99.98M0.0% | $99.98M0.0% | $99.98M— | $0-100% | $96.92M0.0% | ||
| $560.95M0.0% | $560.95M— | $0— | $0-100% | $12.91M0.0% | ||
| -$456.76M-1.2% | -$451.34M-507% | $110.84M+964% | $10.42M-89.1% | $95.35M+5.6% | ||
| -$32.11M+48.8% | -$62.7M-140% | $155.44M+1,053% | -$16.31M+95.0% | -$327.93M-329% | ||
| -$48.07M+36.5% | -$75.68M-16.1% | -$65.17M+18.9% | -$80.4M-11.4% | -$72.14M-4.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NovoCure generate?
- NovoCure (NVCR) generated -$26.9M in operating cash flow over the trailing twelve months.
- What is NovoCure's free cash flow?
- After $21.2M of capital expenditures, NovoCure's free cash flow was -$48.1M over the trailing twelve months, up 33.4% year over year.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
